查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840628

动物用药品市场按产品类型、动物类型、给药途径、适应症、分销管道和最终用户划分－2025-2032年全球预测

Veterinary Pharmaceuticals Market by Products, Animal Type, Mode of Administration, Indications, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，动物用药品市场规模将达到 784.3 亿美元，年复合成长率为 8.60%。

主要市场统计数据
基准年 2024 405.3亿美元
预计年份：2025年 438.8亿美元
预测年份：2032年 784.3亿美元
复合年增长率 (%) 8.60%

临床创新、监管压力和相关人员优先事项的综合框架重新定义了动物用药品的战略要务。

动物用药品产业正处于一个关键的十字路口，科学进步、不断发展的动物照护模式以及日益严格的监管正在汇聚，重新定义产品的研发、分销和应用方式。本出版物综合分析了影响包括製造商、兽医、动物保健网路和终端用户在内的相关人员优先事项的关键因素。它着重阐述了治疗方法创新、抗菌药物管理和商业性动态之间的相互作用，以及这些因素如何影响整个价值链的决策，从而组装了更广泛的背景框架。

包括精准抗寄生虫药物、先进的疫苗平台以及专为伴侣动物用药设计的製剂在内的新型治疗方法，正在挑战传统的产品系列和运作模式。同时，支付方和采购管道要求提供更清晰的临床价值和安全性证据，监管机构也加强了对残留物和风险缓解措施的监测。这些压力既带来了限制，也带来了机会。专注于标靶适应症开发、改善给药系统和整合服务的公司，最能满足不断变化的临床需求。此次招聘将着重于了解技术进步和政策变化如何相互作用，从而为行业参与者创造近期战略要务。

生物技术、数位诊断和监管倡议领域的策略格局正在发生变化，这正在重塑研发、分销和投资重点。

一系列横跨实验室、农场和诊所的变革正在改变这一切。生物技术驱动的疫苗和新型抗菌药物正在重塑治疗管道，而数位健康工具和远端医疗正日益影响伴侣动物和牲畜的治疗行为和依从性。这些技术进步缩短了诊断时间，实现了更精准的干预，改变了对传统频谱药物的需求模式，并将投资转向了标靶性强、循证的产品。

同时，监管机构和社会对抗生素合理使用的日益重视，正在加速推广含药饲料替代品、生技药品和预防策略，促使生产商重新思考其产品线并重新评估其生命週期策略。随着线上药局和综合兽医服务的日益普及，市场参与企业也正在应对不断变化的采购管道，这些管道推动了新的分销和商业化模式的出现。金融机构和策略伙伴优先考虑那些展现出强大的资料整合能力、可扩展的生产能力和敏捷的供应链管理能力的公司。总而言之，最显着的变化包括技术成熟度的提高、监管力度的加强、通路的演变以及投资者对数据主导、可扩展资产组合的偏好。

2025年关税调整将如何改变动物用药品价值链的筹资策略、供应链在地化和贸易条款？

2025年实施的关税调整的累积影响正在加剧整个动物用药品生态系统在成本、供应链和策略采购方面的考虑。製造商和经销商正在重新调整筹资策略，以减轻关税相关的成本上涨，同时确保能够从全球供应商获得关键的活性药物原料药、辅料和特殊包装材料。这种调整促使他们更加重视供应商多元化、将关键生产流程外包以及重新谈判贸易条款，以在不影响品质或合规性的前提下维持利润率稳定。

这些金融逆风也影响下游相关人员，包括兽医诊所和畜牧场，迫使他们优化库存并优先考虑高价值干预措施。为此，企业正在加快对本地製造伙伴关係以及能够提供不受关税影响的供应链的合约开发和受託製造厂商的投资。同时，长期策略应对措施包括重新设计产品系列，以减少对关税敏感型投入的依赖，并加强与区域合作伙伴的协作，以简化海关程序和合规文件。这些措施的共同实施将减轻未来贸易衝击的影响，并确保伴侣动物和牲畜能够持续获得治疗。

透过对产品、动物类型、给药方式、适应症、管道和最终用户进行综合細項分析，提供有针对性的开发和商业化策略。

有效的市场区隔能够识别价值创造与临床需求的交集，从而指导产品策略和通路部署。按产品类型划分，市场包括药品、药用饲料和疫苗。药品再细分为止痛药、抗感染药、抗发炎药和抗寄生虫药等次类别。抗感染药进一步分为抗生素和抗真菌药物，抗发炎药分为非类固醇类抗发炎药和类固醇类抗发炎药，抗寄生虫药分为体外寄生虫药和体内寄生虫药。药用饲料涵盖抗生素药用饲料、抗寄生虫药用饲料、生长促进剂、营养药用饲料以及益生菌和益生元药用饲料。疫苗细分则根据平台和风险等级进行，区分灭活疫苗和活病毒疫苗疫苗，并重点阐述每种疫苗的低温运输和监管要求。

伴侣动物分为猫、狗和马，而家畜则分为牛、鸡、羊、山羊和猪。每种动物都有其独特的治疗需求和给药方式。给药途径进一步影响製剂策略，注射剂包括肌肉注射和皮下注射；口服剂型包括胶囊、液体混悬剂、糖浆和锭剂；外用剂型包括乳膏、洗剂和软膏。按适应症细分可以突出关键领域，例如慢性疼痛和急性疼痛管理、免疫系统疾病、感染疾病、代谢和神经系统疾病、整形外科疾病、寄生虫感染疾病和生殖健康，从而指导临床证据的生成和标籤声明。分销管道涵盖线上药局、零售药局和兽医诊所，每种通路的购买行为和监管要求各不相同。最终用户，包括养殖场、宠物饲主和兽医诊所，会影响定价、包装和支援服务。整合这些细分层可以更精确地针对研发投资、商业化计画和上市后监测策略。

美洲、欧洲、中东和非洲以及亚太地区的区域动态和监管差异将决定市场准入、应用和供应链策略。

区域动态对不同地区的法律规范、供应链韧性和商业机会的影响各不相同。在美洲，市场活跃度主要受以下因素驱动：伴侣动物对先进疗法的高接受度、不断进步的兽医实践标准，以及强大的零售和诊所分销网络，这些因素加速了新型配方的推广。不同地区的贸易行为和报销机制存在差异，促使製造商调整定价策略，并强调产品安全性和便利性，以满足宠物饲主和大型农场的需求。

欧洲、中东和非洲的法规环境既严格又成熟度参差不齐。中东和非洲市场既蕴藏成长机会，也面临物流的挑战，例如低温运输基础设施的差异和进口法规的不同。亚太地区的特点是畜牧业快速现代化，对预防性疫苗和药用饲料的需求不断增长，以及在先进疗法投资增加的推动下，伴侣动物市场也在蓬勃发展。供应链考量和本地製造伙伴关係在每个地区都发挥着至关重要的作用，而监管协调工作（如有）将对打入市场策略和产品生命週期管理产生重大影响。

透过整合研发、卓越製造和策略伙伴关係，实现竞争优势差异化，加速生技药品和先进疗法的商业化进程。

该领域的竞争格局呈现出大型跨国公司、专业生物技术公司和灵活高效的契约製造并存的态势。主要企业凭藉其整合能力脱颖而出，将研发实力、先进的生产能力和广泛的商业网络相结合，从而实现生技药品和复杂製剂的快速规模化生产。策略联盟和授权协议十分常见，企业希望藉助利基技术供应商来补充自身内部的专业知识，尤其是在疫苗平台开发和新型抗寄生虫药物领域。

创新资金筹措正日益透过有针对性的伙伴关係来推动，大型企业提供资金和商业化路径，而小型企业则提供科学创新。投资于依从性监测、远端医疗辅助配药以及数据主导的药物安全检测数位化工具的公司，能够加强与兽医和动物饲主的关係。低温运输物流、法规事务和生产品质的卓越营运是持久的差异化优势，能够提供强而有力的临床证据和管理框架也同样重要。总而言之，竞争格局有利于那些将科学创新与严谨的商业化和供应链韧性结合的公司。

采取切实可行的策略行动，协调研发、供应链韧性、管理和数位化商业化，以实现永续的竞争优势。

为了充分发挥临床和商业性价值，产业领导者应围绕两大要务调整策略：创新和供应链韧性。优先发展标靶治疗和预防性生技药品，同时将抗菌药物管理纳入标籤、行销和上市后监测活动，以满足监管机构和社会期望。投资于能够提高患者依从性、减少给药频率和简化给药方式的製剂技术，将获得临床医生和製剂所有者的支持。

同时，我们将调整筹资策略，降低关税风险，并透过多元化的供应商网路和区域製造伙伴关係冗余体系。我们将整合数位互动平台与传统分销管道，强化商业化进程，以支援远端医疗工作流程、依从性监测和资料收集，从而增强真实世界证据的生成。我们将探索合作研究和授权模式，加速新型平台的普及，同时实施严格的药物安全检测和品质体系，以维护相关人员的信任。最后，我们将根据当地法规环境和特定物种的需求调整市场推广计划，确保我们的临床价值提案与当地实践模式相符。

结合主要相关人员访谈、科学文献综述、监管分析和供应链图谱的稳健混合调查方法，确保了可操作的洞见。

本分析采用严谨的调查方法，结合多面向分析，并将主要相关人员的见解与二手科学和监管文献进行三角验证。主要研究包括对兽医、行业高管、生产合作伙伴和分销管道负责人进行结构化访谈，以了解营运现状、未满足的临床需求和采购动态。这些定性资讯与官方监管文件、专家科学研究和公司揭露资讯相结合，用于检验治疗趋势并评估政策变化带来的实际影响。

分析步骤包括按产品类型、物种、给药途径、适应症、分销管道和最终用户进行细分映射，以便对临床需求与商业机会之间的匹配度进行细緻解读。供应链分析着重于采购风险、关税影响和生产能力限制。最后，竞争评估优先考虑研发、生产、法规事务和数位化互动方面的能力。在整个调查方法中，我们确保假设的透明度，并透过多个独立资讯来源验证研究结果，以增强结论和建议的可信度。

总结报告强调了创新协同、整合管理和供应链重组对于将科学进步转化为永续商业性成果的重要性。

总之，在生技药品和标靶治疗的技术创新、不断变化的监管预期以及贸易调整和动态带来的商业性压力等因素的共同推动下，动物用药品行业正经历着剧烈的变革。这些因素迫使企业在产品设计、证据产生和供应链配置方面采取更具策略性的策略。积极实践管理原则、投资合规产品配方并建立抗关税采购管道的企业，将更有能力满足临床医生和宠物主人的期望，同时保持营运利润率。

这些措施包括加速研发疫苗和标靶抗寄生虫药物，以减少对广谱抗生素的依赖；实现生产和物流现代化，以减轻贸易中断的影响；以及应用数位化工具来提升临床决策和用药依从性。透过将创新重点与当地监管细则和终端用户行为相结合，企业可以将科学进步转化为可持续的商业性成果，并改善动物健康。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 更严格的监管促进了牲畜饲料中非抗生素生长促进剂的研发。
  • 整合虚拟咨询和电子配药等功能的远距远端医疗平台在宠物护理领域蓬勃发展
  • 采用单株抗体和新型生技药品标靶治疗犬猫疾病
  • 兽医护理中缓释性注射剂等先进药物传输系统的推广应用
  • 将穿戴式健康监测技术与药物治疗结合，以提高治疗顺从性
  • 扩大植物来源营养补充品和功能性宠物食品的市场，以促进兽医健康预防

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章动物用药品市场产品分类

  • 药物
    • 止痛药
    • 抗感染药物
      • 抗生素
      • 抗真菌药物
    • 抗发炎药
      • 非类固醇类
      • 类固醇
    • 杀寄生虫剂
      • 体外寄生虫杀灭剂
      • 体内杀寄生虫剂
  • 药用饲料
    • 含抗生素的药用饲料
    • 驱虫饲料
    • 生长促进剂
    • 营养和药用饲料
    • 益生菌和益生元处方药用饲料
  • 疫苗
    • 灭活疫苗
    • 活病毒疫苗

第九章 依动物类型分類的动物用药品市场

  • 伴侣动物
    • 猫
    • 狗
    • 马
  • 家畜
    • 牛
    • 家禽
    • 绵羊和山羊
    • 猪

第十章 依给药途径分類的动物用药品市场

  • 注射
    • 肌肉内注射
    • 皮下
  • 口服
    • 胶囊
    • 液体悬浮液和糖浆
    • 药片
  • 局部的
    • 奶油
    • 洗剂
    • 软膏

第十一章动物用药品

  • 慢性疼痛和急性疼痛管理
  • 免疫状态
  • 感染疾病
  • 代谢紊乱
  • 神经系统疾病
  • 整形外科疾病
  • 寄生虫感染疾病
  • 生殖健康

第十二章 按分销管道分類的动物用药品市场

  • 网路药房
  • 零售药房
  • 兽医诊所

第十三章 依最终用户分類的动物用药品市场

  • 动物农场
  • 宠物饲主
  • 兽医诊所

第十四章 按地区分類的动物用药品市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章动物用药品市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国动物用药品市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Aurora Pharmaceutical, Inc.
    • Biogenesis Bago SA
    • Biovac Ltd.
    • Boehringer Ingelheim International GmbH
    • Ceva Sante Animale
    • Chanelle Pharma
    • China Animal Husbandry Industry Co., Ltd.
    • Dechra Pharmaceuticals PLC
    • ECO Animal Health Group PLC
    • Elanco Animal Health Incorporated
    • Heska Corporation
    • Hester Biosciences Limited
    • Indian Immunologicals Ltd.
    • Intas Pharmaceuticals Ltd.
    • Laboratorio Drag Pharma Chile Invetec SA
    • Merck & Co., Inc.
    • Neogen Corporation
    • Norbrook Group
    • Phibro Animal Health Corporation
    • Teknofarma Srl
    • Vetoquinol Group
    • Vetpharma Animal Health SL by Insud Pharma SLU
    • Virbac SA
    • Zendal Group
    • Zoetis Inc.
Product Code: MRR-032F197B035E

The Veterinary Pharmaceuticals Market is projected to grow by USD 78.43 billion at a CAGR of 8.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 40.53 billion
Estimated Year [2025] USD 43.88 billion
Forecast Year [2032] USD 78.43 billion
CAGR (%) 8.60%

Comprehensive framing of clinical innovation, regulatory pressures, and stakeholder priorities that together redefine strategic imperatives in veterinary pharmaceuticals

The veterinary pharmaceuticals sector stands at a pivotal juncture where scientific progress, evolving animal care paradigms, and heightened regulatory scrutiny converge to redefine how products are developed, distributed, and deployed. This introduction synthesizes the critical forces that are shaping stakeholder priorities across manufacturers, veterinarians, animal health networks, and end users. It frames the broader context by emphasizing the interplay between therapeutic innovation, antimicrobial stewardship, and commercial dynamics that influence decision-making across the value chain.

Emerging therapeutic modalities, such as precision antiparasitics, refined vaccine platforms, and formulations tailored to compliance in companion animals, are challenging legacy product portfolios and operational models. Concurrently, payers and procurement channels are demanding clearer evidence of clinical value and safety, while regulatory authorities are tightening oversight on residues and risk mitigation. These pressures are creating both constraints and opportunities: companies focused on targeted indication development, improved delivery systems, and integrated services are best positioned to meet shifting clinical expectations. Throughout this introduction, the emphasis remains on understanding how technological advances and policy shifts interact to create near-term strategic imperatives for industry participants.

Strategic landscape shifts driven by biotechnology, digital diagnostics, and stewardship policies that are reconfiguring development, distribution, and investment priorities

The landscape is being transformed by a suite of converging shifts that extend from the laboratory to the farm and the clinic. Biotechnology-enabled vaccines and novel antimicrobial alternatives are reshaping therapeutic pathways, while digital health tools and telemedicine increasingly influence prescribing behavior and adherence across companion and livestock populations. These technological advances reduce time to diagnosis and enable more precise interventions, thereby altering demand patterns for traditional broad-spectrum drugs and shifting investment toward targeted, evidence-backed products.

At the same time, regulatory and societal emphasis on antimicrobial stewardship is accelerating the adoption of medicated-feed alternatives, biologics, and preventive strategies, prompting manufacturers to reformulate pipelines and revisit lifecycle strategies. Market participants are also contending with evolving procurement channels as online pharmacies and integrated veterinary services gain traction, driving new distribution and commercialization models. Financial sponsors and strategic partners are prioritizing companies that demonstrate robust data packages, scalable manufacturing, and agility in supply chain management. In sum, the most consequential shifts are technological maturation, regulatory tightening, channel evolution, and investor preference for data-driven, scalable asset portfolios.

How 2025 tariff adjustments are reshaping sourcing strategies, supply chain localization, and commercial terms across the veterinary pharmaceuticals value chain

The cumulative impact of tariff adjustments introduced in 2025 has amplified cost, supply chain, and strategic sourcing considerations across the veterinary pharmaceuticals ecosystem. Manufacturers and distributors are recalibrating procurement strategies to mitigate tariff-related cost inflation while preserving access to critical active pharmaceutical ingredients, excipients, and specialized packaging sourced from global suppliers. This recalibration is prompting a renewed emphasis on supplier diversification, nearshoring of critical manufacturing steps, and renegotiation of commercial terms to maintain margin stability without compromising quality or regulatory compliance.

These fiscal headwinds also affect downstream stakeholders, including veterinary clinics and animal farms, which face pressure to optimize inventory and prioritize high-value interventions. In response, companies are accelerating investments in local manufacturing partnerships and contract development and manufacturing organizations that can offer tariff-resilient supply chains. Simultaneously, longer-term strategic responses include redesigning product portfolios to reduce reliance on tariff-exposed inputs and increasing collaboration with regional partners to streamline customs processes and compliance documentation. Collectively, these measures reduce exposure to future trade shocks and support continuity of therapeutic availability for both companion animals and livestock populations.

Integrated segmentation analysis across products, species, administration modes, indications, channels, and end users to inform targeted development and commercialization strategies

Effective segmentation reveals where value creation and clinical need intersect, informing product strategy and channel deployment. When examined by product, the market encompasses Drugs, Medicinal Feed, and Vaccines. Within Drugs, subcategories include Analgesics, Anti-Infectives, Anti-Inflammatories, and Parasiticides, and the anti-infective category further differentiates into Antibiotics and Antifungals while anti-inflammatory therapies separate into Non-Steroidal and Steroidal approaches; parasiticide treatments divide into Ectoparasiticides and Endoparasiticides. Medicinal Feed covers antibiotic medicated feed, antiparasitic medicated feed, growth promoters, nutritional medicated feed, and probiotic and prebiotic medicated feed. Vaccine segmentation is driven by platform and risk profile, distinguishing between inactivated vaccines and live vaccines, each with distinct cold-chain and regulatory implications.

Segmenting by animal type clarifies demand drivers and regulatory pathways, with Companion Animals split into Cats, Dogs, and Horses and Livestock Animals encompassing Cattle, Poultry, Sheep and Goats, and Swine, each species presenting unique therapeutic needs and administration practices. Mode of administration further influences formulation strategy, where Injectable routes include intramuscular and subcutaneous delivery, Oral forms cover capsules, liquid suspensions and syrups, and tablets, and Topical products are formulated as creams, lotions, and ointments; administration mode affects adherence, required caregiver skill, and product stability. Indication-based segmentation highlights focus areas such as chronic and acute pain management, immunological conditions, infectious diseases, metabolic and neurological disorders, orthopedic conditions, parasitic infections, and reproductive health, guiding clinical evidence generation and label claims. Distribution channels span online pharmacies, retail pharmacies, and veterinary clinics, each with different purchasing behaviors and regulatory obligations, while end users consist of animal farms, pet owners, and veterinary hospitals, informing pricing, packaging, and support services. Integrating these segmentation layers enables more precise targeting of R&D investments, commercialization plans, and post-market surveillance strategies.

Regional dynamics and regulatory nuances across the Americas, Europe Middle East Africa, and Asia-Pacific that determine access, adoption, and supply chain strategies

Regional dynamics shape regulatory frameworks, supply chain resilience, and commercial opportunity in distinct ways across geographies. In the Americas, market activity is driven by high adoption rates of advanced therapeutics in companion animals, progressive veterinary practice standards, and a robust network of retail and clinic-based distribution that accelerates uptake of novel formulations. Transactional behaviors and reimbursement nuances vary within the region, prompting manufacturers to adapt pricing strategies and to emphasize product safety and convenience for pet owners and large-scale farms alike.

Europe, the Middle East & Africa combine rigorous regulatory environments with diverse market maturities. Established European markets emphasize antimicrobial stewardship, stringent residue controls, and strong public sector engagement in livestock health, while markets in the Middle East and Africa present both growth opportunities and logistical complexities, including variability in cold-chain infrastructure and differing import regulations. Asia-Pacific is characterized by rapid modernization of livestock operations, intensifying demand for preventive vaccines and medicated feed solutions, and a growing companion animal segment with rising willingness to invest in advanced therapeutics. Supply chain considerations and local manufacturing partnerships play a pivotal role in all regions, and regulatory harmonization efforts, where they exist, materially influence market entry strategies and product lifecycle management.

Competitive differentiation through integrated R&D, manufacturing excellence, and strategic partnerships that accelerate biologics and advanced therapeutic commercialization

Competitive positioning in the sector reflects a mix of large multinational players, specialized biotechnology firms, and agile contract manufacturers. Leading companies differentiate through integrated capabilities that combine R&D strength, advanced manufacturing, and broad commercial networks, enabling rapid scale-up of biologics and complex formulations. Strategic alliances and licensing agreements are common as organizations seek to complement in-house expertise with niche technology providers, particularly in vaccine platform development and novel antiparasitic chemistries.

Innovation is increasingly financed through targeted partnerships, where larger firms provide capital and commercialization pathways while smaller entities supply scientific novelty. Companies that invest in digital tools for adherence monitoring, telehealth-enabled prescribing, and data-driven pharmacovigilance strengthen relationships with veterinarians and animal owners. Operational excellence in cold-chain logistics, regulatory affairs, and manufacturing quality is a persistent differentiator, as is the ability to demonstrate robust clinical evidence and stewardship frameworks. Overall, the competitive landscape rewards firms that combine scientific innovation with disciplined commercialization and supply chain resilience.

Practical strategic actions to align R&D focus, supply chain resilience, stewardship, and digital-enabled commercialization for sustainable competitive advantage

Industry leaders should align strategy with the twin imperatives of innovation and supply chain resilience to capture clinical and commercial value. Prioritize development programs that emphasize targeted therapeutics and preventative biologics, while embedding antimicrobial stewardship into labeling, marketing, and post-market surveillance activities to satisfy regulatory and societal expectations. Investing in formulation technologies that improve patient adherence, reduce dosing frequency, and simplify administration will drive uptake among clinicians and owners alike.

Simultaneously, reconfigure sourcing strategies to reduce tariff exposure and build redundancy through diversified supplier networks and regional manufacturing partnerships. Strengthen commercialization by integrating digital engagement platforms with traditional distribution channels to support telemedicine workflows, adherence monitoring, and data collection that bolster real-world evidence generation. Pursue collaborations and licensing models to accelerate access to novel platforms, while deploying rigorous pharmacovigilance and quality systems to maintain trust across stakeholders. Finally, tailor market entry plans to regional regulatory environments and species-specific needs to ensure alignment between clinical value propositions and local practice patterns.

Robust mixed-methods methodology combining primary stakeholder interviews, scientific literature review, regulatory analysis, and supply chain mapping to ensure actionable insights

The research methodology underpinning this analysis combined a multifaceted approach to ensure robustness, triangulating primary stakeholder insights with secondary scientific and regulatory literature. Primary engagements included structured interviews with veterinarians, industry executives, manufacturing partners, and distribution channel leaders to capture operational realities, unmet clinical needs, and procurement dynamics. These qualitative inputs were synthesized with public regulatory documents, peer-reviewed scientific studies, and corporate disclosures to validate therapeutic trends and to assess the practical implications of policy shifts.

Analytical steps included segmentation mapping across product types, species, administration routes, indications, distribution channels, and end users, enabling granular interpretation of where clinical demand aligns with commercial opportunity. Supply chain analysis focused on sourcing exposures, tariff impacts, and manufacturing capacity constraints. Finally, competitive assessment prioritized capabilities in R&D, manufacturing, regulatory affairs, and digital engagement. Throughout the methodology, care was taken to ensure transparency of assumptions and to corroborate findings through multiple independent sources, enhancing confidence in the conclusions and recommendations presented.

Conclusive synthesis emphasizing innovation alignment, stewardship integration, and supply chain redesign to translate scientific advances into durable commercial outcomes

In conclusion, the veterinary pharmaceuticals sector is navigating a period of substantive change driven by innovation in biologics and targeted therapeutics, evolving regulatory expectations, and commercial pressures stemming from trade adjustments and shifting distribution dynamics. These factors collectively require companies to be more strategic in product design, evidence generation, and supply chain configuration. Firms that proactively integrate stewardship principles, invest in formulating products that enhance compliance, and establish tariff-resilient sourcing will be better positioned to meet clinician and owner expectations while preserving operational margins.

The path forward involves a balanced approach: accelerate development of vaccines and targeted antiparasitics that reduce reliance on broad-spectrum antimicrobials, modernize manufacturing and logistics to mitigate trade-related disruptions, and adopt digital tools that enhance clinical decision-making and adherence. By aligning innovation priorities with regional regulatory nuances and end-user behaviors, organizations can translate scientific advances into durable commercial outcomes and improved animal health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising regulatory restrictions driving development of non-antibiotic growth promoters in livestock feed
  • 5.2. Surge in telemedicine platforms integrating virtual consultations and e-prescribing for companion animal care
  • 5.3. Adoption of monoclonal antibody and novel biologics for targeted treatment of canine and feline diseases
  • 5.4. Expansion of advanced drug delivery systems such as sustained-release injectables in veterinary therapeutics
  • 5.5. Integration of wearable health monitoring technologies with pharmacotherapy to enhance treatment compliance
  • 5.6. Growing market for plant-derived nutraceuticals and functional pet foods for preventive veterinary health

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Pharmaceuticals Market, by Products

  • 8.1. Drugs
    • 8.1.1. Analgesics
    • 8.1.2. Anti-Infectives
      • 8.1.2.1. Antibiotics
      • 8.1.2.2. Antifungals
    • 8.1.3. Anti-Inflammatories
      • 8.1.3.1. Non-Steroidal
      • 8.1.3.2. Steroidal
    • 8.1.4. Parasiticides
      • 8.1.4.1. Ectoparasiticides
      • 8.1.4.2. Endoparasiticides
  • 8.2. Medicinal Feed
    • 8.2.1. Antibiotic Medicated Feed
    • 8.2.2. Antiparasitic Medicated Feed
    • 8.2.3. Growth Promoters
    • 8.2.4. Nutritional Medicated Feed
    • 8.2.5. Probiotic & Prebiotic Medicated Feed
  • 8.3. Vaccines
    • 8.3.1. Inactivated Vaccines
    • 8.3.2. Live Vaccines

9. Veterinary Pharmaceuticals Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
    • 9.1.3. Horses
  • 9.2. Livestock Animals
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep & Goats
    • 9.2.4. Swine

10. Veterinary Pharmaceuticals Market, by Mode of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Subcutaneous
  • 10.2. Oral
    • 10.2.1. Capsules
    • 10.2.2. Liquid Suspension & Syrup
    • 10.2.3. Tablets
  • 10.3. Topical
    • 10.3.1. Creams
    • 10.3.2. Lotions
    • 10.3.3. Ointments

11. Veterinary Pharmaceuticals Market, by Indications

  • 11.1. Chronic & Acute Pain Management
  • 11.2. Immunological Conditions
  • 11.3. Infectious Diseases
  • 11.4. Metabolic Disorders
  • 11.5. Neurological Disorders
  • 11.6. Orthopedic Disorders
  • 11.7. Parasitic Infections
  • 11.8. Reproductive Health

12. Veterinary Pharmaceuticals Market, by Distribution Channel

  • 12.1. Online Pharmacies
  • 12.2. Retail Pharmacies
  • 12.3. Veterinary Clinics

13. Veterinary Pharmaceuticals Market, by End User

  • 13.1. Animal Farms
  • 13.2. Pet Owners
  • 13.3. Veterinary Hospitals

14. Veterinary Pharmaceuticals Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Veterinary Pharmaceuticals Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Veterinary Pharmaceuticals Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Aurora Pharmaceutical, Inc.
    • 17.3.2. Biogenesis Bago S.A.
    • 17.3.3. Biovac Ltd.
    • 17.3.4. Boehringer Ingelheim International GmbH
    • 17.3.5. Ceva Sante Animale
    • 17.3.6. Chanelle Pharma
    • 17.3.7. China Animal Husbandry Industry Co., Ltd.
    • 17.3.8. Dechra Pharmaceuticals PLC
    • 17.3.9. ECO Animal Health Group PLC
    • 17.3.10. Elanco Animal Health Incorporated
    • 17.3.11. Heska Corporation
    • 17.3.12. Hester Biosciences Limited
    • 17.3.13. Indian Immunologicals Ltd.
    • 17.3.14. Intas Pharmaceuticals Ltd.
    • 17.3.15. Laboratorio Drag Pharma Chile Invetec S.A.
    • 17.3.16. Merck & Co., Inc.
    • 17.3.17. Neogen Corporation
    • 17.3.18. Norbrook Group
    • 17.3.19. Phibro Animal Health Corporation
    • 17.3.20. Teknofarma S.r.l.
    • 17.3.21. Vetoquinol Group
    • 17.3.22. Vetpharma Animal Health S.L. by Insud Pharma S.L.U.
    • 17.3.23. Virbac S.A.
    • 17.3.24. Zendal Group
    • 17.3.25. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCTS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCTS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. VETERINARY PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. VETERINARY PHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY PHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NON-STEROIDAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NON-STEROIDAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NON-STEROIDAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NON-STEROIDAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NON-STEROIDAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NON-STEROIDAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY STEROIDAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY STEROIDAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY STEROIDAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY STEROIDAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY STEROIDAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY STEROIDAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ENDOPARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ENDOPARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ENDOPARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ENDOPARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTIC MEDICATED FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTIC MEDICATED FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTIC MEDICATED FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTIC MEDICATED FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTIC MEDICATED FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTIC MEDICATED FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITIC MEDICATED FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITIC MEDICATED FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITIC MEDICATED FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITIC MEDICATED FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITIC MEDICATED FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITIC MEDICATED FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL MEDICATED FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL MEDICATED FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL MEDICATED FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL MEDICATED FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL MEDICATED FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL MEDICATED FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PROBIOTIC & PREBIOTIC MEDICATED FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PROBIOTIC & PREBIOTIC MEDICATED FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PROBIOTIC & PREBIOTIC MEDICATED FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PROBIOTIC & PREBIOTIC MEDICATED FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PROBIOTIC & PREBIOTIC MEDICATED FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PROBIOTIC & PREBIOTIC MEDICATED FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LOTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LOTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LOTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LOTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LOTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LOTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-20